期刊文献+

小鼠beta防御素2原核表达与抗菌作用的初步研究

Prokaryotic Expression and Purification and Activity Analysis of Mouse Beta Defensins 2
下载PDF
导出
摘要 构建小鼠β-防御素-2(mouse beta defensins 2,mBD2)原核表达质粒pET32/mBD2,进行蛋白诱导表达及纯化,测定并纯化蛋白的抗菌活性。旨在为进一步研究其生物学特性奠定基础。通过腹腔注射脂多糖(lipopoly-saccharide,LPS)建立小鼠急性时相反应,采用RT-PCR方法扩增mBD2成熟肽,经KpnI和XhoI双酶切后插入相同酶切的pET-32a(+)载体,构建的重组质粒。将鉴定正确的重组质粒转化大肠杆菌表达菌株BL21(DE3),采用异丙基-D-硫代半乳糖苷(IPTG)诱导融合蛋白的表达。通过镍亲和层析获得纯化的融合蛋白。将融合蛋白采用肠激酶酶切、洗脱并用滤纸片法测定目的蛋白的抗菌活性。成功构建了原核表达质粒pET32a(+)/mBD2,并转化工程菌BL21(DE3)。在0.25 mmol/L IPTG、30℃诱导4 h条件下获得的融合蛋白。采用抑菌试验证实蛋白具有一定的抑制革兰阳性菌及阴性菌生长的作用。本研究成功构建了pET32/mBD2原核表达质粒,得到了在大肠杆菌中稳定表达mBD2蛋白。 The prokaryotic expression vector,pET32a(+)/mBD2 was constructed and transfed into E.coli BL21,respectively.Then the expression of mBD2 in E.coli BL21 and function was studied.mBD gene was amplified by RT-PCR from sensitive mouse which LPS was injected beforehand.The amplified mBD2 gene fragment was inserted into the plasmid pET-32a(+)that was digested with Kpn I and Xho I.The recombinant plasmid pET32/mBD2 was transformed into E.coli JM109 and selected with ampicillin.The positive clones containing recombinant plasmid pET32/mBD2 were verified by restriction endonucleases Kpn I and Xho I,and then sequenced.mBD2-TRX fused protein expression in the E.coli BL21(ED3)was identified by SDS-PAGE.The expressed recombinant protein was purifier by His-tag purification kit,digested by enterokinase.Then its antibacterial activity was tested.The pET32a(+)/mBD2 vectors were constructed successfully and correctly.The BL21(DE3)transformed recombinant plasmid pET32a(+)/mBD2 had expressed mBD2-TRX fused protein effectively under the conditions of 0.25 mmol/L IPTG and 30℃.The activity assay demonstrated the peptides had ability against three standard stains.
出处 《生物技术通报》 CAS CSCD 北大核心 2012年第10期95-99,共5页 Biotechnology Bulletin
基金 新疆自然科学基金项目(2011211 A048) 新疆高校重点基金项目(XJEDU2009120)
关键词 小鼠beta防御素2(mBD2) 原核表达 SDS-PAGE 抑菌作用 Mouse beta-defensin 2(mBD2) Prokaryotic expression SDS-PAGE Antibacterial activity
  • 相关文献

参考文献16

  • 1Ganz T, Selsted ME, Lehrer RI. Defensins. Europe Haemato, 1990, 44(1):1-8.
  • 2Edith M, Tomas G, Robert L. Antibacterial peptide sand other endo- genous peptide antibiotics of vertebrates. Leukocyte Biology, 1995, 58 ( 5 ) : 128-139.
  • 3Ganz T, Selsted ME, Szklarek D, et al. Defensins. Natural peptide antibiotics of human neutrophils. Clin Invest, 1985, 76 ( 4 ) : 1427- 1435.
  • 4Ahn HS, Cho W, Kang SH, et al. Design and synthesis of novel antimicrobial peptides on the basis of a helical domain of Tenecin 1, an insect defensin protein, and structure-activity relationship study. Peptides, 2006, 27 ( 4 ) : 640-648.
  • 5Goldman MJ. Human beta defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell, 1997, 88 ( 4 ) : 553- 560.
  • 6Giacometi A, Cirioni O, Delprete MS, et al. Combination studies between polycationic peptide and clinically used anti-biotics against Gram-positive and Gram-negative bacteria. Peptides, 2000, 21 ( 8 ): 1155-1160.
  • 7陈民钧,Janet Hindler,Susan Munro.规范抗茵药药敏试验合理向临床报告检测结果[J].中华检验医学杂志,2009,32(3):249-256. 被引量:13
  • 8Ganz T. Defensins : antimicrobial peptides of innate immunity. Nat Rev Immungl, 2003, 3 ( 9 ) : 710-720.
  • 9Zanetti M. Cathelieidins, muhifunctional peptides of the innate immunity. Leukoc Biol, 2004, 75 ( 1 ) : 39-48.
  • 10Yang D, Biragyan A, Hoover DM, et al. Multiple roles of anti mic- robial defensins, cathelicidins, and eosinophil derived neurotoxin in host defense. Annu Rev Immunol, 2004, 22 : 181-215.

二级参考文献39

  • 1覃文周.血清半胱氨酸蛋白酶抑制剂C检测对诊断早期肾功能损害的价值[J].广西医学院学报,2008,18(3):445-446. 被引量:17
  • 2陆焰,武建,宋朝辉.半胱氨酸蛋白酶抑制剂C在早期肾功能损害诊断中的应用价值[J].中国卫生检验杂志,2007,17(3):485-486. 被引量:17
  • 3Clinical and laboratory standards institute. M2-A10. performance standards for antimicrobial disk susceptibility tests; Approved standard-tenth edition. CLSI,2009.
  • 4Clinical and laboratory standards institute. MT-AS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard-eighth edition. CLSI,2009.
  • 5Clinical and laboratory standards institute. M11-A7. Methods for antimicrobial susceptibility testing of anaerobic bacteria; Approved standard- seventh edition. CLSI,2007.
  • 6Clinical and laboratory standards institute. M23-A3. Development of in vitro susceptibility testing criteria and quality control parameters ; Approved guideline-third edition. CLSI,2008.
  • 7Clinical and laboratory standards institute. M31-A3. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; Approved standard-third edition. CLSI,2008.
  • 8Clinical and laboratory standards institute. M37-A3. Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobial agents; Approved guideline-third edition. CLSI,2008.
  • 9Clinical and laboratory standards institute. M39-A3. Analysis and presentation of cumulative antimierobial susceptibility test data; Approved guideline-third edition. CLSI,2009.
  • 10Clinical and laboratory standards institute. M100-S19. Performance standards for antimicrobial susceptibility testing; Nineteenth informational supplement. CLSI,2009.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部